Cargando…

Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure

BACKGROUND: Heart failure (HF) courses with chronic inflammatory process and alterations in lipid metabolism may aggravate the disease. The aim was to test whether the severity of HF, using brain natriuretic peptide (BNP) as a marker, is associated with alterations in functional aspects of HDL, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinelli, Ana Elisa M., Maranhão, Raul C., Carvalho, Priscila O., Freitas, Fatima R., Silva, Bruna M. O., Curiati, Milena N. C., Kalil Filho, Roberto, Pereira-Barretto, Antonio Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195750/
https://www.ncbi.nlm.nih.gov/pubmed/30342531
http://dx.doi.org/10.1186/s12944-018-0888-0
_version_ 1783364449348878336
author Martinelli, Ana Elisa M.
Maranhão, Raul C.
Carvalho, Priscila O.
Freitas, Fatima R.
Silva, Bruna M. O.
Curiati, Milena N. C.
Kalil Filho, Roberto
Pereira-Barretto, Antonio Carlos
author_facet Martinelli, Ana Elisa M.
Maranhão, Raul C.
Carvalho, Priscila O.
Freitas, Fatima R.
Silva, Bruna M. O.
Curiati, Milena N. C.
Kalil Filho, Roberto
Pereira-Barretto, Antonio Carlos
author_sort Martinelli, Ana Elisa M.
collection PubMed
description BACKGROUND: Heart failure (HF) courses with chronic inflammatory process and alterations in lipid metabolism may aggravate the disease. The aim was to test whether the severity of HF, using brain natriuretic peptide (BNP) as a marker, is associated with alterations in functional aspects of HDL, such as lipid transfer, cholesterol ester transfer protein (CETP) and lecithin-cholesterol acyltransferase (LCAT) concentration. METHODS: Twenty-five HF patients in NYHA class I/II and 23 in class III/IV were enrolled. Plasma lipids, apolipoproteins, CETP, LCAT, oxidized-LDL (oxLDL) and paraoxonase-1 (PON-1) activity were determined. Lipid transfer from a donor artificial nanoparticle to HDL was measured by in vitro assay. RESULTS: Total cholesterol (p = 0.049), LDL-C (p = 0.023), non-HDL-C (p = 0.029) and CETP, that promotes lipid transfer among lipoproteins (p = 0.013), were lower in III/IV than in I/II group. Triglycerides, HDL-C, apo A-I, apo B, oxLDL, LCAT, enzyme that catalyzes serum cholesterol esterification, PON-1 activity, and in vitro transfers of cholesterol, triglycerides and phospholipids to HDL, important steps in HDL metabolism, were equal. IL-8 was higher in III/IV (p = 0.025), but TNFα, IL-1β, IL-6 and MCP-1 were equal. BNP was negatively correlated with CETP (r = − 0.294; p = 0.042) and positively correlated with IL-8 (r = 0.299; p = 0.039). CONCLUSIONS: Our results disclosed the relationship between CETP levels and HF severity, by comparing two HF groups and by correlation analysis. Lower CETP levels may be a marker of HF aggravation and possibly of worse prognosis. Practical applications of this initial finding, as the issue whether CETP could be protective against HF aggravation, should be explored in larger experimental and clinical studies.
format Online
Article
Text
id pubmed-6195750
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61957502018-10-30 Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure Martinelli, Ana Elisa M. Maranhão, Raul C. Carvalho, Priscila O. Freitas, Fatima R. Silva, Bruna M. O. Curiati, Milena N. C. Kalil Filho, Roberto Pereira-Barretto, Antonio Carlos Lipids Health Dis Research BACKGROUND: Heart failure (HF) courses with chronic inflammatory process and alterations in lipid metabolism may aggravate the disease. The aim was to test whether the severity of HF, using brain natriuretic peptide (BNP) as a marker, is associated with alterations in functional aspects of HDL, such as lipid transfer, cholesterol ester transfer protein (CETP) and lecithin-cholesterol acyltransferase (LCAT) concentration. METHODS: Twenty-five HF patients in NYHA class I/II and 23 in class III/IV were enrolled. Plasma lipids, apolipoproteins, CETP, LCAT, oxidized-LDL (oxLDL) and paraoxonase-1 (PON-1) activity were determined. Lipid transfer from a donor artificial nanoparticle to HDL was measured by in vitro assay. RESULTS: Total cholesterol (p = 0.049), LDL-C (p = 0.023), non-HDL-C (p = 0.029) and CETP, that promotes lipid transfer among lipoproteins (p = 0.013), were lower in III/IV than in I/II group. Triglycerides, HDL-C, apo A-I, apo B, oxLDL, LCAT, enzyme that catalyzes serum cholesterol esterification, PON-1 activity, and in vitro transfers of cholesterol, triglycerides and phospholipids to HDL, important steps in HDL metabolism, were equal. IL-8 was higher in III/IV (p = 0.025), but TNFα, IL-1β, IL-6 and MCP-1 were equal. BNP was negatively correlated with CETP (r = − 0.294; p = 0.042) and positively correlated with IL-8 (r = 0.299; p = 0.039). CONCLUSIONS: Our results disclosed the relationship between CETP levels and HF severity, by comparing two HF groups and by correlation analysis. Lower CETP levels may be a marker of HF aggravation and possibly of worse prognosis. Practical applications of this initial finding, as the issue whether CETP could be protective against HF aggravation, should be explored in larger experimental and clinical studies. BioMed Central 2018-10-20 /pmc/articles/PMC6195750/ /pubmed/30342531 http://dx.doi.org/10.1186/s12944-018-0888-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Martinelli, Ana Elisa M.
Maranhão, Raul C.
Carvalho, Priscila O.
Freitas, Fatima R.
Silva, Bruna M. O.
Curiati, Milena N. C.
Kalil Filho, Roberto
Pereira-Barretto, Antonio Carlos
Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure
title Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure
title_full Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure
title_fullStr Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure
title_full_unstemmed Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure
title_short Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure
title_sort cholesteryl ester transfer protein (cetp), hdl capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195750/
https://www.ncbi.nlm.nih.gov/pubmed/30342531
http://dx.doi.org/10.1186/s12944-018-0888-0
work_keys_str_mv AT martinellianaelisam cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure
AT maranhaoraulc cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure
AT carvalhopriscilao cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure
AT freitasfatimar cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure
AT silvabrunamo cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure
AT curiatimilenanc cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure
AT kalilfilhoroberto cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure
AT pereirabarrettoantoniocarlos cholesterylestertransferproteincetphdlcapacityofreceivingcholesterolandstatusofinflammatorycytokinesinpatientswithsevereheartfailure